- Veradigm (MDRX, Financial) employs AI to enhance real-world evidence generation for GLP-1 receptor agonists.
- The new AI-driven approach extracts insights from electronic health records (EHR), identifying side effects and discontinuation reasons.
- Veradigm will present findings at ISPOR 2025, focusing on GLP-1 usage and therapy discontinuation.
Veradigm (MDRX), a leader in healthcare data and technology solutions, has announced a significant advancement in the use of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for GLP-1 receptor agonists, including semaglutide and tirzepatide. This new capability leverages the vast data from the Veradigm Network to uncover insights that were previously hidden within electronic health records (EHR).
The AI-driven approach allows researchers to extract valuable, contextual insights into critical factors such as side effects, discontinuation drivers, and social determinants of health (SDoH). This advancement is particularly crucial for GLP-1 therapies that are transforming the management of type 2 diabetes and obesity, where understanding patient experiences and reasons for treatment discontinuation can significantly enhance outcomes and therapeutic strategies.
Key capabilities of Veradigm’s AI-driven curation include identifying discontinuation drivers, monitoring side effects, flagging off-brand use, tracking comorbidities, and surfacing social and behavioral contexts that influence health outcomes. These insights are derived from both structured and unstructured EHR data across diverse populations.
Veradigm plans to showcase their research findings at ISPOR 2025, with a focus on GLP-1 persistence and real-world reasons for therapy discontinuation, during Poster Session 2 on May 14, from 4:00–7:00 PM EDT. This ongoing research strengthens Veradigm's mission to provide valuable insights for life science research, regulatory engagement, and value-based decision-making.
